Premium
Tissue factor and tissue factor pathway inhibitor
Author(s) -
Price G. C.,
Thompson S. A.,
Kam P. C. A.
Publication year - 2004
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/j.1365-2044.2004.03679.x
Subject(s) - tissue factor , tissue factor pathway inhibitor , coagulation , medicine , thromboplastin , immune system , cancer research , microbiology and biotechnology , immunology , biology
Summary The classical ‘cascade/waterfall’ hypothesis formulated to explain in vitro coagulation organised the amplification processes into the intrinsic and extrinsic pathways. Recent molecular biology and clinical data indicate that tissue factor/factor‐VII interaction is the primary cellular initiator of coagulation in vivo . The process of blood coagulation is divided into an initiation phase followed by a propagation phase. The discovery of tissue factor pathway inhibitor further supports the revised theory of coagulation. Tissue factor is also a signalling receptor. Recent evidence has shown that blood‐borne tissue factor has an important procoagulant function in sepsis, atherosclerosis and cancer, and other functions beyond haemostasis such as immune function and metastases.